Alzheimer’s spotted before it strikes

What if we could detect Alzheimer's disease years before the first symptoms appear?

One of the greatest challenges in the fight against Alzheimer's disease is that the pathological process begins long before clinical symptoms emerge. By the time memory impairment becomes apparent, substantial and often irreversible brain damage is already underway.

A new international study, involving Prof. Shay Rahimipour together with collaborators from leading research institutions, offers a promising new perspective on early disease detection.

The researchers successfully identified toxic protein aggregates that form at the very earliest stages of Alzheimer's disease, long before they evolve into the hallmark pathological features detectable by current diagnostic methods. These microscopic aggregates are believed to play a critical role in initiating the neurodegenerative cascade that ultimately leads to cognitive decline.

As part of the study, the team developed novel molecular probes capable of selectively recognizing and labeling these early-stage toxic assemblies, enabling their detection at unprecedented stages of disease development.

Importantly, the technology is already advancing toward clinical evaluation. To accelerate its translation into real-world applications, a startup company, ApexBio, has been established with the goal of developing this breakthrough platform into both a diagnostic and therapeutic solution for millions of individuals affected by Alzheimer's disease worldwide.

Congratulations to Prof. Shay Rahimipour and the entire research team for their contribution to advancing the understanding and early detection of one of the most complex and impactful diseases of our time.

Read the full paper published in Alzheimer's Association Journals:
View the article